Multiparametric Mapping of Knee Joint with Magnetic Resonance Fingerprinting

项目总结 骨关节炎(OA)是一种退行性关节疾病，在美国有2700多万人患病 独自一人。这一庞大的受影响人口以及随之而来的严重的办公自动化能力的丧失导致了大量的费用 医疗保健系统。OA的特征是生物化学、结构和形态上的降解 关节软骨细胞外基质(ECM)成分。ECM主要由两个小组组成 包括蛋白多糖(PG)和胶原纤维在内的大分子。软骨退行性变的早期诊断 将需要非侵入性地检测PG浓度和胶原完整性变化的能力 形态会发生变化。T1、T2和T1ρ松弛时间受这些病理过程的影响 是世界上使用最广泛的生化软骨磁共振序列。 该提案的首要目标是开发、优化和翻译磁共振指纹图谱 (MRF)框架，允许同时、形态、体积和定量多参数 将[T1，T2，T1ρ，B1+和质子密度(PD)]映射到膝关节的时间(≤10分钟)要短得多 在标准3T临床扫描仪上进行常规个体参数标测。建议的基于MRF的 多参数标测方法可以很容易地结合到常规研究/临床方案中，用于多参数标测 没有外源性造影剂的膝关节组织评估，可以作为未来的成像 骨关节炎疾病修正疗法的生物标记物。

PROJECT SUMMARY Osteoarthritis (OA) is a degenerative joint disease, affecting more than 27 million people in the United States alone. This large affected population and the severe consequent debility of OA lead to significant expenses to the health care system. OA is characterized by biochemical, structural and morphologic degradation of components of the extracellular matrix (ECM) of articular cartilage. The ECM is composed of primarily two groups of macromolecules including proteoglycan (PG) and collagen fibers. Early diagnosis of cartilage degeneration would require the ability to non-invasively detect changes in PG concentration and collagen integrity before morphological changes occur. T1, T2 and T1ρ relaxation times are affected by these pathological processes and are the most widely used biochemical cartilage MRI sequences worldwide. The overarching goal of this proposal is to develop, optimize, and translate the magnetic resonance fingerprinting (MRF) framework, which allows for simultaneous, morphological, volumetric, and quantitative multiparametric mapping [T1, T2, T1ρ, B1+ and proton density (PD)] to the knee joint in a much shorter time (≤10 minutes) than conventional individual parametric mapping on a standard 3T clinical scanner. The proposed MRF-based multiparametric mapping approach can be easily incorporated into routine research/clinical protocols for multi- tissue assessment of the knee joint without exogenous contrast agents and could serve as future imaging biomarkers for disease modifying therapies for OA.